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INTRODUCTION: In Brazil, patients with chronic myeloid leukemia (CML) in the chronic phase were not given first-line ima-
tinib treatment until 2008. Therefore, there was a long period of time between diagnosis and the initiation of imatinib therapy for 
many patients. This study aims to compare the major molecular remission (MMR) rates of early versus late imatinib therapy in 
chronic phase CML patients.
METHODS: Between May 2002 and November 2007, 44 patients with chronic phase CML were treated with second-line imatinib 
therapy at the Hematology Unit of the Ophir Loyola Hospital (Belém, Pará, Brazil). BCR-ABL transcript levels were measured at 
approximately six-month intervals using quantitative polymerase chain reaction.
RESULTS: The early treatment group presented a 60% probability of achieving MMR, while the probability for those patients who 
received late treatment was 40%. The probability of either not achieving MMR within one year of the initiation of imatinib therapy 
or losing MMR was higher in patients who received late treatment (79%), compared with patients who received early treatment 
(21%, odds ratio=5.75, P=0.012). The probability of maintaining MMR at 30 months of treatment was 80% in the early treatment 
group and 44% in the late treatment group (P=0.0005).
CONCLUSIONS: For CML patients in the chronic phase who were treated with second-line imatinib therapy, the probability of 
achieving and maintaining MMR was higher in patients who received early treatment compared with those patients for whom the 
time interval between diagnosis and initiation of imatinib therapy was longer than one year.
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INTRODUCTION
Chronic myeloid leukemia (CML) is a disease that 
originates from a hematopoietic stem cell characterized 
by the reciprocal chromosomal translocation t(9;22)
(q34;q11). This chromosomal translocation, also known 
as a Philadelphia (Ph) chromosome, is responsible for the 
formation of the fusion gene BCR-ABL.1,2 This chimeric 
gene codes for a cytoplasmic protein with constitutive 
tyrosine kinase activity, which has a fundamental role in the 
leukemogenic process.3,4
Historically, CML treatment was unable to halt the 
course of the disease, and almost all patients progressed to 
the blastic phase of CML after three to five years. Recently, 
however, imatinib mesylate has been found to induce 
hematologic and cytogenetic remission and, consequently, 
to modify the progression of CML.5 Cytogenetic remission 
is considered an important parameter for assessment of the 
therapeutic success of imatinib treatment.6 However, even 
patients with cytogenetic remission may present minimal 
residual disease7 that can only be detected by polymerase 
chain reaction (PCR).8 Real-time PCR (RT-PCR) from 732
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cDNA allows for the quantification of BCR-ABL transcript 
levels with a sensitivity of one in one hundred thousand 
cells. In patients with complete cytogenetic remission, 
quantification of this molecular response by RT-PCR 
correlates with the duration of remission of the disease.8,9
In Brazil, federal health authorities did not reimburse 
first-line imatinib therapy for patients with CML in the 
chronic phase until 2008. In many cases, this circumstance 
led to a long time interval between diagnosis and the 
initiation of imatinib therapy, which was eventually 
reimbursed only after patients had progressed to the 
accelerated phase or become intolerant to interferon therapy. 
The objective of this study was to compare the major 
molecular remission (MMR) rates of patients receiving early 
versus late imatinib therapy after the diagnosis of CML.
METHODS
Patients
Between May 2002 and November 2007, we evaluated 
44 patients with chronic phase CML who were undergoing 
treatment at the Hematology Unit of the Ophir Loyola 
Hospital. All patients received second-line imatinib therapy 
(400 mg/day), due to intolerance or resistance to interferon, 
according to the criteria laid out in Resolution SAS 431 of 
the Ministry of Health of Brazil (2001). Two groups were 
established according to the time interval between the 
diagnosis of CML and the initiation of imatinib therapy: the 
early treatment group (time interval shorter than one year 
between diagnosis and treatment) and the late treatment 
group (time interval more than one year). MMR was defined 
as a reduction of at least three logs (0,1%) in relation to the 
baseline (100%) in BCR-ABL transcript levels.
The Brazilian National Ethical Committee approved this 
study in June 2001 (no. CONEP 2318).
Quantitative real-time polymerase chain reaction 
RT-PCR (TaqMan, Applied Biosystems) was utilized to 
quantify BCR-ABL expression relative to the control gene 
ABL, according to Lemos et al.10 The control gene ABL was 
chosen according to the recommendation of Europe Against 
Cancer (EAC).11,12
BCR-ABL transcript quantification based on the inter-
national scale
Reduction in the BCR-ABL transcript level was 
calculated on the basis of the international scale,13 by direct 
calculation of the cycle threshold (CT) for the BCR-ABL/
ABL ratio was employed, according to Lemos et al.,10 but 
without the use of the standard curve. To calculate the 
basal BCR-ABL transcript levels, the mean BCR-ABL/ABL 
(BCR-ABLL%) ratios of 38 patients were obtained before 
the initiation of imatinib therapy; 11 of these patients had 
the B2A2 transcript, and 29 had the B3A2 transcript. The 
difference in the transcript levels between the two groups 
was not statistically significant. Afterward, the MMREq 
was calculated, which is the BCR-ABL/ABLL equivalent of 
MMR established in the International Randomized Study of 
Interferon and STI571 (IRIS).14 The conversion factor (CF) 
was then calculated to convert the results to the international 
scale, dividing 0.1 (the value attributed to MMR on the 
international scale) by the MMREq value. Finally, the CF 
was multiplied by BCR-ABLL to obtain the quantification 
according to the international scale (BCR-ABL/ABLIS).
Statistical analysis
Simple logistic regression was utilized to calculate the 
probability of MMR in the early and late treatment groups. 
The difference between the time of CML diagnosis and 
the initiation of imatinib therapy in the group achieving 
MMR and the group not achieving MMR was evaluated 
by Student’s t-test for independent samples. Maintenance 
of MMR was estimated by the Kaplan-Meier method, 
considering a reduction of ≥3 logs of BCR-ABL expression 
as the event of interest. The level of significance was set at 
0.05 (two-tailed).
RESULTS
Of the 44 patients evaluated, 18 (41%) were men, and 26 
(59%) were women. Their ages ranged from 22 to 76 years, 
with a median age of 49 years. In 16 patients (37%), the time 
interval between the diagnosis of CML and the initiation of 
imatinib therapy was shorter than one year; in 28 patients 
(63%), this time was one year or longer.
The probability of achieving MMR was 60% in the 
group who received early treatment, versus 40% in the late 
treatment group. The probability of not reducing BCR-ABL 
transcript levels by three logs within one year of treatment, 
or of losing MMR, was 79% in the late treatment group and 
21% in the early treatment group (P=0.012, odds ratio=5.75) 
(Figure 1).
The patients who sustained MMR up to the thirtieth month 
of treatment started the use of imatinib about 14.4 months 
after the diagnosis (standard deviation [SD], 13.6 months) 
(Figure 3). The patients who achieved MMR showed a 
probability of maintaining MMR after 30 months of therapy 
of 80% if they received early treatment with imatinib. On the 733
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DISCUSSION
In the 2003 IRIS study,14 39% of patients with CML in 
the chronic phase who received first-line imatinib therapy 
showed a reduction of three logs in their BCR-ABL transcript 
levels within the first year of treatment. Moreover, patients 
achieving molecular remission showed a smaller risk of 
progression over the next 12 months. In the present study, 
the MMR rate was 31%, and the mean duration of MMR 
was 26 months (SD±15). The difference in MMR rates 
between the IRIS study and this one could be attributed to 
different time intervals between diagnosis and the initiation 
of imatinib therapy in each study. In the IRIS study, patients 
with recently diagnosed and previously untreated CML 
received first-line imatinib therapy, while in our study, 
imatinib was used as a second-line therapy. In a study 
conducted by Aziz et al. in Pakistan, the authors concluded 
that the biology of CML in Pakistani patients was not 
different from that in patients from developing countries.15 
However, regarding Brazil, local treatment policies have 
delayed the initiation of imatinib therapy, thus affecting the 
results regarding molecular remission rates, which otherwise 
could be similar to those results observed in the IRIS study. 
Matsuo et al. evaluated 99 patients with CML in the 
chronic phase treated with imatinib; 43 of these patients 
had been recently diagnosed, and 56 patients had been 
previously treated. The overall survival and progression-free 
survival rates were 88.7% and 85.2%, respectively, in the 
first group and 79.8% and 76.6% in the second.16 Because 
no statistically significant differences were observed in any 
of the main study endpoints, the authors concluded that 
patients receiving first-line imatinib therapy have the same 
outcome as those patients who had been previously treated 
with interferon or hydroxyurea. However, the authors did not 
report the time interval between diagnosis and the initiation 
of imatinib therapy, suggesting that the time elapsed between 
diagnosis and initiation of imatinib therapy in the previously 
treated group was not long enough to produce a meaningful 
difference.
In the present study, due to Brazilian federal legislation 
that would not reimburse first-line imatinib therapy until 
2008, all patients received previous treatment with another 
drug. Because of the large variation in the time interval 
between diagnosis and the initiation of imatinib therapy, 
reaching up to 192 months, it was possible to define two 
different groups according to this variable. The probability 
of achieving MMR was significantly higher in the early 
treatment group, compared with the late treatment group.
The exact time interval between diagnosis of CML 
and the initiation of imatinib therapy that discriminates 
between early and late treatment is not well defined in the 
Figure 1 - Probability of achieving major molecular remission (MMR) with 
early or late imatinib therapy (P=0.012, odds ratio=5.75). MMR-: patients 
who did not achieve MMR within one year of treatment or lost MMR; 
MMR+: patients who achieved MMR within one year of treatment
Figure 2 - Kaplan-Meier estimates of major molecular remission (MMR) 
according to the time interval elapsed between diagnosis and the initiation 
of imatinib therapy
Figure 3 - Months between diagnosis and initiation of treatment, according 
to major molecular remission (MMR) status after 30 months of treatment
other hand, this probability was only 44% for patients who 
received late treatment (P=0.0005) (Figure 2).734
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literature. We found that patients who sustained MMR up 
to the thirtieth month of therapy initiated imatinib therapy 
approximately one year after the diagnosis (mean of 14.4 
months) (Figure 3). We also observed that patients who 
started imatinib therapy within one year of diagnosis had 
an 80% probability of sustaining MMR into the thirtieth 
month of treatment, while in the late treatment group, this 
probability was reduced to 44%.
Therefore, in view of our results, we suggest that 12 
months should be considered the upper limit of the time 
interval for initiating imatinib treatment for CML. Moreover, 
after this time interval, the probability that a patient will lose 
MMR increases considerably.
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